Executive Wealth Management LLC Purchases 1,510 Shares of PRA Health Sciences Inc (NASDAQ:PRAH)
Executive Wealth Management LLC grew its position in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 15.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,030 shares of the medical research company’s stock after acquiring an additional 1,510 shares during the quarter. Executive Wealth Management LLC’s holdings in PRA Health Sciences were worth $1,094,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRAH. Motco boosted its position in PRA Health Sciences by 937.0% in the first quarter. Motco now owns 280 shares of the medical research company’s stock worth $31,000 after purchasing an additional 253 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in shares of PRA Health Sciences during the 2nd quarter valued at $49,000. Financial Gravity Wealth Inc. bought a new stake in shares of PRA Health Sciences during the 1st quarter valued at $53,000. Manchester Capital Management LLC bought a new stake in shares of PRA Health Sciences during the 1st quarter valued at $57,000. Finally, CENTRAL TRUST Co raised its stake in shares of PRA Health Sciences by 28.2% during the 1st quarter. CENTRAL TRUST Co now owns 842 shares of the medical research company’s stock valued at $93,000 after purchasing an additional 185 shares during the period. Hedge funds and other institutional investors own 97.98% of the company’s stock.
A number of analysts recently issued reports on PRAH shares. Mizuho set a $100.00 price objective on PRA Health Sciences and gave the company a “hold” rating in a research note on Friday, May 3rd. Leerink Swann started coverage on PRA Health Sciences in a research note on Tuesday, July 2nd. They set a “market perform” rating and a $105.00 price objective on the stock. BidaskClub upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Finally, Svb Leerink reiterated a “market perform” rating on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. Eight research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $113.40.
PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Wednesday, July 31st. The medical research company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.11 by $0.11. The firm had revenue of $763.31 million for the quarter, compared to analyst estimates of $764.95 million. PRA Health Sciences had a return on equity of 26.64% and a net margin of 5.39%. The company’s revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.00 EPS. As a group, sell-side analysts expect that PRA Health Sciences Inc will post 4.63 earnings per share for the current year.
PRA Health Sciences Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Recommended Story: What is the significance of the death cross?
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.